CTAD 2024 | Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial

Todd Feaster, PsyD, Acumen Pharmaceuticals, Carmel, IN, discusses the use of a validated p-tau217 assay to screen participants for the ALTITUDE-AD trial of sabirnetug. This assay is being used to identify participants likely to be amyloid-positive, which has reduced the rate of negative amyloid PET scans. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.